Literature DB >> 24720503

TH17 cells are increased in the peripheral blood of patients with SAPHO syndrome.

Davide Firinu1, Maria Pina Barca, Maria Maddalena Lorrai, Silvia Perra, Stefano Cabras, Emma Muggianu, Maria Luisa Di Martino, Paolo Emilio Manconi, Stefano R Del Giacco.   

Abstract

To assess whether the immune derangement previously observed in SAPHO syndrome could be linked to variations in blood TH1, TH2 or TH17 lymphocytes frequency. Seven SAPHO patients with a protracted course of the disease were studied ex-vivo for intracellular cytokines production by means of flow-cytometry and compared with matched groups of Psoriatic Arthritis patients and healthy controls. The Kruskal-Wallis test on the median of the three categories showed that there is a significant association between the TH17 levels and the category (p value = 0.02474). The mean and variance for the proportion of IL-17 producing CD4+ cells were compared between groups showing significant differences between SAPHO versus PsA subgroup (p = 0.05) and SAPHO versus healthy controls (p = 0.008). Interestingly, activation of TH17 axis, but not of TH1 and TH2, has been found, and can be observed both in patients with different activity of the disease or treated with different drugs. The TH17 increase in peripheral blood of our SAPHO subjects resembles the one recently found in patients with different AIDs. Novel therapeutic options in these patients may therefore include IL-17 blockade.

Entities:  

Keywords:  Autoinflammatory; CRMO; TH17; inflammation; interleukin-1β; osteitis

Mesh:

Substances:

Year:  2014        PMID: 24720503     DOI: 10.3109/08916934.2014.906582

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  15 in total

Review 1.  SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment.

Authors:  Davide Firinu; Vanessa Garcia-Larsen; Paolo Emilio Manconi; Stefano R Del Giacco
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

Review 2.  Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review.

Authors:  Massimo Cugno; Roberta Gualtierotti; Pier Luigi Meroni; Angelo Valerio Marzano
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 3.  Advances in the genetically complex autoinflammatory diseases.

Authors:  Michael J Ombrello
Journal:  Semin Immunopathol       Date:  2015-06-16       Impact factor: 9.623

4.  SAPHO syndrome with enthesopathy.

Authors:  Chin-Fang Su; Yu-Chuan Shen; Hsien-Tzung Liao; Chang-Youh Tsai
Journal:  BMJ Case Rep       Date:  2019-01-07

Review 5.  Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment.

Authors:  Francesco Cianci; Angelo Zoli; Elisa Gremese; Gianfranco Ferraccioli
Journal:  Clin Rheumatol       Date:  2017-07-19       Impact factor: 2.980

6.  Enhanced migration and adhesion of peripheral blood neutrophils from SAPHO patients revealed by RNA-Seq.

Authors:  Yuxiu Sun; Chen Li; Mengmeng Zhu; Shen Zhang; Yihan Cao; Qiao Yang; Pengfei Zhao; Guangrui Huang; Anlong Xu
Journal:  Orphanet J Rare Dis       Date:  2019-08-08       Impact factor: 4.123

7.  Serum-derived extracellular vesicles inhibit osteoclastogenesis in active-phase patients with SAPHO syndrome.

Authors:  Yanpan Gao; Yanyu Chen; Lun Wang; Chen Li; Wei Ge
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-04-16       Impact factor: 5.346

8.  Genome-Wide Association Identifies Risk Pathways for SAPHO Syndrome.

Authors:  Ruikun Cai; Yichao Dong; Mingxia Fang; Yuxuan Fan; Zian Cheng; Yue Zhou; Jianen Gao; Feifei Han; Changlong Guo; Xu Ma
Journal:  Front Cell Dev Biol       Date:  2021-03-18

9.  Abundance alteration of nondominant species in fecal-associated microbiome of patients with SAPHO syndrome.

Authors:  Jianhua Zhen; Yuxiu Sun; Pengfei Zhao; Chen Li; Hesong Wang; Yini Li; Lu Zhao; Li Wang; Guangrui Huang; Anlong Xu
Journal:  BMC Microbiol       Date:  2021-05-30       Impact factor: 3.605

10.  Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab).

Authors:  Akshay Flora; Richard Holland; Annika Smith; John W Frew
Journal:  JAAD Case Rep       Date:  2021-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.